Skip to content

Basic research on the application of Zhuang medicinal oil combined with medicated thread moxibustion to mediate oxidative stress in the prevention and treatment of MCI based on TRPV1

Basic research on the application of Zhuang medicinal oil combined with medicated thread moxibustion to mediate oxidative stress in the prevention and treatment of MCI based on TRPV1

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000746
Enrollment
Unknown
Registered
2024-11-27
Start date
2023-12-27
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild cognitive impairment

Interventions

Non-MCI healthy control group:none
Zhuang medicine oil combined with medicine line moxibustion group:Zhuang medicine oil combined with medicine line moxibustion

Sponsors

the First Affiliated Hospital of Guangxi University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1: Patients who meet the diagnostic criteria for MCI; 2: There is memory impairment (self-reported and confirmed by an insider) MMSE score is between 24-27; 3: Age 55-75 years old; 4: Other cognitive functions are relatively normal or mildly impaired; 5: Daily life ability and social occupation are not affected; 6: The memory impairment has not yet reached the diagnostic criteria for dementia; 7: Exclude any other systemic diseases that can cause brain dysfunction; 8: The subject or guardian signs the informed consent form

Exclusion criteria

Exclusion criteria: 1: Exclude subjective cognitive decline SCD and dementia; 2: Other neurological diseases other than suspected early-stage AD that can lead to cognitive decline such as Parkinson's disease vascular dementia brain tumors etc; 3: People with severe heart liver kidney and other systemic diseases such as insufficiency and other systemic diseases that can cause cognitive decline such as thyroid dysfunction anemia hepatic encephalopathy renal encephalopathy etc; 4: Those with abnormal brain structures such as intellectual development disabilities brain infections cerebral infarction cerebral hemorrhage and those with a history of severe head trauma or other diseases involving the central nervous system thus affecting the evaluation of neuropsychological scales; 5: Have a history of depression anxiety bipolar disorder schizophrenia and other mental illnesses; 6: Patients who have used other drugs that may cause changes in cognitive function or failure of important organs such as heart brain and kidne

Design outcomes

Primary

MeasureTime frame
Montreal cognitive assessment(MoCA);

Secondary

MeasureTime frame
Animal fluency test ( AFT);Mini-mental state examination (MMSE);auditory verbal learning test-Huashan version (AVLT-H);Shape trails test A(STT-A)/shape trails test B(STT-B);Functional Activities Questionnaire(FAQ);Serum Aß1-42, Tau and P-tau, BDNF levels;Short form of the World Health Organization Quality of Life Measurement Scale;Boston Naming Test(BNT);P300 latency and amplitude;Mini-mental state examination (MMSE);

Countries

China

Contacts

Public ContactZhao Li hua

First Affiliated Hospital Guangxi University of Chinese Medicine

zhaolh67@163.com13006913108

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026